Glaukos Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GKOS research report →
Range $150 – $255
Price Chart
About the company
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma.
- CEO
- Thomas William Burns
- IPO
- 2015
- Employees
- 1,094
- HQ
- Aliso Viejo, CA, US
AI snapshot
Six angles, distilled from the data.
The stock remains in a strong multi-month uptrend, trading well above its 200-day moving average and not far from its 52-week high. That keeps the regime constructive, with momentum still favoring buyers after a large recovery from the 52-week low.
Street sentiment is firmly positive, with a Buy consensus and an average target above the current share price. Recent action has been mostly target raises rather than rating downgrades, including BTIG lifting its target to $252 and several firms resetting targets into the $225-$255 range.
The earnings pattern has improved, with 6 beats in the last 8 quarters and the most recent report delivering a 0.47 EPS beat versus a -0.12 estimate. Analysts still expect a return to profitability, with next-year EPS at 1.40, so shareholders should watch whether margin progress holds and guidance supports that path.
Recent insider activity skews to net selling, led by President & COO Joseph Gilliam's discretionary sales alongside multiple automatic exemption transactions. The automatic awards and tax-related moves are noise; the signal is the cluster of sales, including a larger two-tranche sale in November and a prior sale by the CEO in April.
Gross margin is strong at 81.1%, but profitability remains under pressure with a -8.95% operating margin and -24.6% net margin. Revenue growth is still robust at 58% year over year, and the balance sheet is solid with $278.8 million in cash versus $139.6 million of debt and positive net cash.
GKOS stands out as a higher-growth ophthalmic device name with a premium multiple versus the broader healthcare equipment group. The setup favors a valuation that reflects execution, not current earnings power, with consensus targets clustered above the market price.
- Market Cap
- $14.40B
- P/E
- -82.74
- Fwd P/E
- 360.61
- PEG
- 0.73
- P/S
- 20.86
- P/B
- 20.04
- EV/EBITDA
- -115.64
- Div Yield
- 0.00%
- Gross Margin
- 81.13%
- Op Margin
- -9.17%
- Net Margin
- -24.60%
- ROE
- -24.91%
- ROIC
- -7.22%
Latest fiscal year · YoY change
- Revenue
- $507.44M+32.3%
- Gross Profit
- $393.22M+35.8%
- Op Income
- $-86,733,000
- Net Income
- $-187,691,000-28.2%
- EPS
- $-3.28-18.4%
- OCF Growth
- +24.4%
- FCF Growth
- +20.1%
- Beta
- 0.69
- RSI (14)
- 62
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Glaukos delivered a record third quarter, driven by strong Epioxa and iDose TR launches, and raised 2026 sales guidance while introducing a preliminary $1 billion 2027 revenue outlook.· October 28, 2026
- Q3 net sales hit a record $211 million, up 58% year over year, with non-GAAP gross margin expanding to about 88%.
- Epioxa generated about $53 million in sales in its early launch phase, while U.S. glaucoma sales reached $118.6 million and iDose TR contributed about $76 million.
- Management raised full-year 2026 net sales guidance to $775 million to $785 million, up from $680 million to $700 million previously, and introduced preliminary 2027 revenue guidance of $1 billion.
- The company said access is now established for about 90% of commercial lives for Epioxa and about 80% of Medicaid lives, with the site-of-care network serving roughly 90% of the U.S. population.
- Gross margin and operating leverage improved as the mix shifted toward Epioxa and iDose TR, and management said operating expenses will still grow in Q4 and into 2027 as launches and R&D investments continue.
Glaukos reported record third quarter consolidated net sales of $211 million, up 58% versus the year-ago quarter. Non-GAAP gross margin expanded by nearly 400 basis points year over year to approximately 88%, non-GAAP net income was $28.5 million, non-GAAP EPS was $0.47, and the company generated more than $50 million in cash. Corneal Health net sales were $59 million, up 154% year over year, driven by approximately $53 million of Epioxa sales. U.S. Glaucoma net sales were $118.6 million, up 47% year over year, with iDose TR sales of approximately $76 million. International Glaucoma net sales were $33.4 million, up 13% reported and 15% constant currency. For the full year 2026, management raised net sales guidance to $775 million to $785 million from $680 million to $700 million. They also said iDose TR is now expected to reach the low $280 millions for 2026, versus prior expectations of $275 million to $280 million. Operating expenses are expected to grow 25% to 30% in Q4, with full-year 2026 operating expenses around plus or minus $630 million. Management introduced highly preliminary 2027 revenue guidance of $1 billion.
Tom Burns framed the quarter as evidence that Glaukos is becoming a more diversified ophthalmology leader with two major growth engines: iDose TR and Epioxa. He emphasized that the company is still prioritizing top-line growth and market expansion while investing in commercial infrastructure, clinical development, and disease awareness. His tone was confident and expansionary, but he repeatedly noted that the company will keep reinvesting heavily into pipeline programs and launch support.
Alex Thurman highlighted strong gross margin expansion to about 88% and said the company is maintaining operating leverage despite continued investment. He guided Q4 operating expense growth to 25% to 30% and said full-year 2026 operating expenses should land around plus or minus $630 million, which implies just over 30% year-over-year growth. He also said gross margin durability should hold because Epioxa and iDose TR are expected to remain a larger share of revenue mix.
Analysts focused on the new 2027 revenue guide, Epioxa launch metrics, prior authorization friction, the buy-and-bill channel, and the potential impact of Medicare LCDs on iDose TR. Management said the $1 billion 2027 outlook includes scenarios where LCDs are proposed or finalized close to current expectations and still leaves the company confident in reaching that level. On Epioxa, management said access and workflow are improving, with more than 200 established sites of care exiting Q3, more than 300 contracted deployments in the pipeline, and payer access established for about 90% of commercial lives and 80% of Medicaid lives. On LCDs, they said the MACs are still reviewing the evidence, the comment period is over, and Glaukos is preparing both clinical evidence and potential reconsideration paths if restrictions are finalized.
The bull case from this call is that both major launches are gaining traction faster than expected, while margin and cash generation are already improving. Management also sounded confident that Epioxa can expand the keratoconus market over time through awareness, screening, and broader access, while iDose TR continues to build clinical and commercial momentum.
The main risks discussed were reimbursement and coverage complexity, especially around possible iDose TR LCD restrictions and the still-early Epioxa launch process. Management also acknowledged that prior authorization, payer workflows, and site-of-care expansion can be slow and uneven, and that operating expenses will keep rising as the company funds awareness campaigns, commercial expansion, and a broad R&D pipeline.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 96.0%
- Shares Outstanding
- 59.20M
- Float Shares
- 56.85M
of shares held by institutions
381 13F filers
Buy/sell ratio 0.33. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 9.32M | ▼ 215.87K |
| Vanguard Group Inc | 6.02M | ▼ 26.03K |
| Janus Henderson Group Ltd. | 5.35M | ▲ 2.33M |
| Jupiter Topco LLC | 4.86M | ▲ 4.86M |
| Vanguard Portfolio Management LLC | 3.30M | ▼ 17.94K |
| Primecap Management Co | 3.08M | ▲ 35.49K |
| Fmr LLC | 2.87M | ▲ 2.49M |
| Vanguard Capital Management LLC | 2.55M | ▼ 4.33K |
| State Street Corp | 2.31M | ▼ 2.95K |
| Millennium Management LLC | 1.58M | ▲ 407.32K |
| Holocene Advisors, LP | 1.51M | ▲ 131.22K |
| Geode Capital Management, LLC | 1.45M | ▼ 14.41K |
Held by 474 ETFs
Biggest fund positions in GKOS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 9, 24 | Burns Thomas William | other | 3,907 |
| Nov 16, 26 | Gilliam Joseph E | other | 200 |
| Nov 16, 26 | Gilliam Joseph E | other | 279 |
| Nov 16, 26 | Gilliam Joseph E | other | 200 |
| Nov 16, 26 | Gilliam Joseph E | other | 100 |
| Nov 16, 26 | Gilliam Joseph E | other | 82 |
| Nov 16, 26 | Gilliam Joseph E | sell | 861 |
| Nov 16, 26 | Gilliam Joseph E | other | 279 |
| Nov 16, 26 | Gilliam Joseph E | other | 200 |
| Nov 16, 26 | Gilliam Joseph E | other | 100 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our GKOS coverage
Recent articles, reports, and earnings notes.

Glaukos (GKOS): Growth Surge Meets Premium Valuation
Glaukos is scaling rapidly on iDose TR and Epioxa, with Q3 revenue up 58% and 2027 sales guidance topping $1.0B. The stock still screens as a Hold because premium valuation and ongoing losses leave limited margin for error.

Glaukos Corporation (GKOS) jumps on record Q3 results
Glaukos Corporation (GKOS) jumps after reporting record third-quarter sales, raising 2026 guidance and unveiling a preliminary $1 billion 2027 sales target. The stronger growth outlook, margin expansion and analyst target hikes helped push the stock above its prior close and 52-week high in after-hours trading.

Glaukos Corporation (GKOS) Jumps 18.5% on Q3 Beat
Glaukos Corporation (GKOS) jumps after a strong third-quarter report featuring record sales, rapid corneal-health growth, positive net income, and higher 2026 guidance. The move reflects renewed investor confidence in the company’s ophthalmology platform, though the stock now trades near the top of analyst expectations.
Want a deeper read on GKOS?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
AI analysis · Last refreshed November 20, 2026 · Live quote · Not investment advice